Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Shenzhen Key Laboratory of Gene and Antibody Therapy, Center for Biotechnology and Biomedicine, State Key Laboratory of Chemical Oncogenomics, State Key Laboratory of Health Sciences and Technology, Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong, 518055, China.
Adv Sci (Weinh). 2023 Apr;10(12):e2300180. doi: 10.1002/advs.202300180. Epub 2023 Feb 17.
Neuroinflammation, for which microglia are the predominant contributors, is a significant risk factor for cognitive dysfunction. Riboflavin (also known as vitamin B2) ameliorates cognitive impairment via anti-oxidative stress and anti-inflammation properties; however, the underlying mechanisms linking riboflavin metabolism and microglial function in cognitive impairment remain unclear. Here, it is demonstrated that riboflavin kinase (RFK), a critical enzyme in riboflavin metabolism, is specifically expressed in microglia. An intermediate product of riboflavin, flavin mononucleotide (FMN), inhibited RFK expression via regulation of lysine-specific methyltransferase 2B (KMT2B). FMN supplementation attenuated the pro-inflammatory TNFR1/NF-κB signaling pathway, and this effect is abolished by KMT2B overexpression. To improve the limited anti-inflammatory efficiency of free FMN, a biomimetic microglial nanoparticle strategy (designated as MNPs@FMN) is established, which penetrated the blood brain barrier with enhanced microglial-targeted delivery efficiency. Notably, MNPs@FMN ameliorated cognitive impairment and dysfunctional synaptic plasticity in a lipopolysaccharide-induced inflammatory mouse model and in a 5xFAD mouse model of Alzheimer's disease. Taken together, biomimetic microglial delivery of FMN may serve as a potential therapeutic approach for inflammation-dependent cognitive decline.
神经炎症是认知功能障碍的一个重要危险因素,其中小胶质细胞是主要贡献者。核黄素(又称维生素 B2)通过抗氧化应激和抗炎作用改善认知障碍;然而,核黄素代谢与小胶质细胞功能在认知障碍中的联系的潜在机制尚不清楚。在这里,研究表明核黄素激酶(RFK),一种核黄素代谢中的关键酶,特异性表达在小胶质细胞中。核黄素的一种中间产物黄素单核苷酸(FMN)通过调节赖氨酸特异性甲基转移酶 2B(KMT2B)来抑制 RFK 的表达。FMN 补充剂减弱了促炎 TNFR1/NF-κB 信号通路,而这种作用被 KMT2B 的过表达所消除。为了提高游离 FMN 的有限抗炎效率,建立了一种仿生小胶质细胞纳米颗粒策略(命名为 MNPs@FMN),它具有增强的血脑屏障穿透性和小胶质细胞靶向递送效率。值得注意的是,MNPs@FMN 改善了脂多糖诱导的炎症小鼠模型和阿尔茨海默病 5xFAD 小鼠模型中的认知障碍和功能障碍性突触可塑性。总之,仿生小胶质细胞递送 FMN 可能成为一种治疗炎症相关认知能力下降的潜在方法。